Relmada Therapeutics, Inc. (RLMD) Stock Grade

About Relmada Therapeutics, Inc.'s fundamentals

Relmada Therapeutics is a biotech company with a market capitalization of $190.7 million that reported zero revenue growth year-over-year and posted a net loss in its latest annual statement, resulting in a net margin of 0.0%. The company does not pay a dividend, and standard valuation metrics like P/E ratio and return on equity are not meaningful given the absence of profitability. As a pre-revenue or early-stage biotech firm, Relmada's financial performance reflects typical characteristics of development-stage pharmaceutical companies that are investing in research and development rather than generating commercial returns.